HomeBUSINESS
BUSINESS

Meiji Grants Carbapenem Rights to Spero Outside Japan, Asia
(Oct.13.2017)

Meiji Seika Pharma has sealed a licensing deal with Spero Therapeutics, granting the US biotech worldwide development and commercialization rights for tebipenem pivoxil, an oral form of a carbapenem-class antibiotic, excluding Japan and 13 Asian countries, the two companies said ...
(LOG IN FOR FULL STORY)

News Calendar